Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2016
|
| gptkbp:ATCCode |
gptkb:R03DX08
|
| gptkbp:CASNumber |
gptkb:146612-99-9
|
| gptkbp:contraindication |
hypersensitivity to reslizumab
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:reslizumab
|
| gptkbp:hasMolecularFormula |
C6470H9956N1726O2016S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cinqair
|
| gptkbp:indication |
severe asthma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
gptkb:IL-5_antagonist
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
anaphylaxis
myalgia oropharyngeal pain increased creatine phosphokinase |
| gptkbp:target |
gptkb:interleukin-5
|
| gptkbp:bfsParent |
gptkb:reslizumab
|
| gptkbp:bfsLayer |
7
|